Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
The lethality of patients with ovarian cancer (OC) remains high. Current treatment strategies often do not lead to the desired outcome due to the development of therapy resistance, resulting in high relapse rates. Additionally, clinical trials testing immunotherapy against OC have failed to reach si...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/7/1792 |
| _version_ | 1827732109420134400 |
|---|---|
| author | Yani Berckmans Yannick Hoffert Ann Vankerckhoven Erwin Dreesen An Coosemans |
| author_facet | Yani Berckmans Yannick Hoffert Ann Vankerckhoven Erwin Dreesen An Coosemans |
| author_sort | Yani Berckmans |
| collection | DOAJ |
| description | The lethality of patients with ovarian cancer (OC) remains high. Current treatment strategies often do not lead to the desired outcome due to the development of therapy resistance, resulting in high relapse rates. Additionally, clinical trials testing immunotherapy against OC have failed to reach significant results to date. The OC tumor microenvironment and specifically myeloid-derived suppressor cells (MDSC) are known to generate immunosuppression and inhibit the anti-tumor immune response following immunotherapy treatment. Our review aims to characterize potential candidate treatments to target MDSC in OC through drug-repurposing. A literature search identified repurposable compounds with evidence of their suppressing the effect of MDSC. A total of seventeen compounds were withheld, of which four were considered the most promising. Lurbinectedin, metformin, celecoxib, and 5-azacytidine have reported preclinical effects on MDSC and clinical evidence in OC. They have all been approved for a different indication, characterizing them as the most promising candidates for repurposing to treat patients with OC. |
| first_indexed | 2024-03-11T00:45:00Z |
| format | Article |
| id | doaj.art-8ac883b1478c44038a21c7cfea8fddf9 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T00:45:00Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-8ac883b1478c44038a21c7cfea8fddf92023-11-18T20:53:54ZengMDPI AGPharmaceutics1999-49232023-06-01157179210.3390/pharmaceutics15071792Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential CandidatesYani Berckmans0Yannick Hoffert1Ann Vankerckhoven2Erwin Dreesen3An Coosemans4Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, Leuven Cancer Institute, Katholieke Universiteit Leuven, 3000 Leuven, BelgiumClinical Pharmacology and Pharmacotherapy Unit, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, BelgiumLaboratory of Tumor Immunology and Immunotherapy, Department of Oncology, Leuven Cancer Institute, Katholieke Universiteit Leuven, 3000 Leuven, BelgiumClinical Pharmacology and Pharmacotherapy Unit, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, BelgiumLaboratory of Tumor Immunology and Immunotherapy, Department of Oncology, Leuven Cancer Institute, Katholieke Universiteit Leuven, 3000 Leuven, BelgiumThe lethality of patients with ovarian cancer (OC) remains high. Current treatment strategies often do not lead to the desired outcome due to the development of therapy resistance, resulting in high relapse rates. Additionally, clinical trials testing immunotherapy against OC have failed to reach significant results to date. The OC tumor microenvironment and specifically myeloid-derived suppressor cells (MDSC) are known to generate immunosuppression and inhibit the anti-tumor immune response following immunotherapy treatment. Our review aims to characterize potential candidate treatments to target MDSC in OC through drug-repurposing. A literature search identified repurposable compounds with evidence of their suppressing the effect of MDSC. A total of seventeen compounds were withheld, of which four were considered the most promising. Lurbinectedin, metformin, celecoxib, and 5-azacytidine have reported preclinical effects on MDSC and clinical evidence in OC. They have all been approved for a different indication, characterizing them as the most promising candidates for repurposing to treat patients with OC.https://www.mdpi.com/1999-4923/15/7/1792ovarian cancerdrug repurposingmyeloid-derived suppressor cellstreatment strategies |
| spellingShingle | Yani Berckmans Yannick Hoffert Ann Vankerckhoven Erwin Dreesen An Coosemans Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates Pharmaceutics ovarian cancer drug repurposing myeloid-derived suppressor cells treatment strategies |
| title | Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates |
| title_full | Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates |
| title_fullStr | Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates |
| title_full_unstemmed | Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates |
| title_short | Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates |
| title_sort | drug repurposing for targeting myeloid derived suppressor cell generated immunosuppression in ovarian cancer a literature review of potential candidates |
| topic | ovarian cancer drug repurposing myeloid-derived suppressor cells treatment strategies |
| url | https://www.mdpi.com/1999-4923/15/7/1792 |
| work_keys_str_mv | AT yaniberckmans drugrepurposingfortargetingmyeloidderivedsuppressorcellgeneratedimmunosuppressioninovariancanceraliteraturereviewofpotentialcandidates AT yannickhoffert drugrepurposingfortargetingmyeloidderivedsuppressorcellgeneratedimmunosuppressioninovariancanceraliteraturereviewofpotentialcandidates AT annvankerckhoven drugrepurposingfortargetingmyeloidderivedsuppressorcellgeneratedimmunosuppressioninovariancanceraliteraturereviewofpotentialcandidates AT erwindreesen drugrepurposingfortargetingmyeloidderivedsuppressorcellgeneratedimmunosuppressioninovariancanceraliteraturereviewofpotentialcandidates AT ancoosemans drugrepurposingfortargetingmyeloidderivedsuppressorcellgeneratedimmunosuppressioninovariancanceraliteraturereviewofpotentialcandidates |